Aditxt Therapeutics: Funding, Investors & Team (Oct 2026)
Aditx Therapeutics is a biotechnology company developing a novel nucleic acid-based technology to selectively suppress immune cells involved in the rejection of transplanted tissues and organs. The company was founded in 2017 by Amro Albanna and is based in Loma Linda, California, United States.
Aditxt Therapeutics has raised $35.2M across 3 funding rounds on record, the most recent an undisclosed round of $1.2M announced in Aug 2024.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aditxt Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Aditxt Therapeutics Funding Rounds
Aditxt Therapeutics raised $20.0M in a Post-IPO Equity announced in Sep 2022.
1.6 years later, an undisclosed round of $14.0M was announced in Apr 2024.
4 months later, an undisclosed round of $1.2M was announced in Aug 2024.
Aditxt Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Aditxt Therapeutics Funding Compared to Other Biotechnology Startups
Aditxt Therapeutics' latest round of $1.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aditxt Therapeutics in Biotechnology and Loma Linda
Companies Similar to Aditxt Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Aditxt Therapeutics Funding FAQs
What does Aditxt Therapeutics do?
Aditx Therapeutics is a biotechnology company developing a novel nucleic acid-based technology to selectively suppress immune cells involved in the rejection of transplanted tissues and organs. The company was founded in 2017 by Amro Albanna and is based in Loma Linda, California, United States.
How much funding has Aditxt Therapeutics raised?
Aditxt Therapeutics has raised $35.2M across 3 rounds on record. The most recent is an undisclosed round of $1.2M announced in Aug 2024.
When did Aditxt Therapeutics last raise funding?
Aditxt Therapeutics' most recent funding round on record is an undisclosed round of $1.2M, announced in Aug 2024.
Who founded Aditxt Therapeutics?
FundedIQ lists Amro Albanna (Founder) at Aditxt Therapeutics.
Where is Aditxt Therapeutics headquartered?
Aditxt Therapeutics is based in Loma Linda, California, United States.
How many employees does Aditxt Therapeutics have?
Aditxt Therapeutics is in the 11-50 employee band.
How does Aditxt Therapeutics' funding compare to other Biotechnology startups?
Aditxt Therapeutics' latest round of $1.2M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Aditxt Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aditxt Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.